A review of the clinical efficacy and tolerability of almotriptan in acute migraine

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Almotriptan is a serotonin (5-hydroxytryptamine, 5-HT)1B/1D-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consistency of response across three attacks and patients continue to respond to almotriptan for up to 1 year. Results from two comparative studies and a meta-analysis of 53 randomised, placebo-controlled studies of oral triptans in > 24,000 patients, confirm that almotriptan 12.5 mg demonstrates comparable efficacy with sumatriptan 50 and 100 mg. The incidence of treatment-related adverse events with almotriptan is comparable to that of placebo and significantly lower than that with sumatriptan. Drug-drug interaction studies indicate that almotriptan may be coadministered with other commonly prescribed drugs without dose modification. Almotriptan can be recommended as first-line treatment for acute migraine.

Original languageEnglish (US)
Pages (from-to)1157-1163
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume4
Issue number7
DOIs
StatePublished - Jul 1 2003

Fingerprint

Migraine Disorders
Sumatriptan
Placebos
Receptor, Serotonin, 5-HT1B
Tryptamines
almotriptan
Drug Interactions
Pharmaceutical Preparations
Meta-Analysis
Serotonin
Therapeutics
Incidence

Keywords

  • Adverse events
  • Almotriptan
  • Efficacy
  • Migraine
  • Triptans

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A review of the clinical efficacy and tolerability of almotriptan in acute migraine. / Dodick, David William.

In: Expert Opinion on Pharmacotherapy, Vol. 4, No. 7, 01.07.2003, p. 1157-1163.

Research output: Contribution to journalArticle

@article{58c963096f7e4e90a5d2152579114b76,
title = "A review of the clinical efficacy and tolerability of almotriptan in acute migraine",
abstract = "Almotriptan is a serotonin (5-hydroxytryptamine, 5-HT)1B/1D-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consistency of response across three attacks and patients continue to respond to almotriptan for up to 1 year. Results from two comparative studies and a meta-analysis of 53 randomised, placebo-controlled studies of oral triptans in > 24,000 patients, confirm that almotriptan 12.5 mg demonstrates comparable efficacy with sumatriptan 50 and 100 mg. The incidence of treatment-related adverse events with almotriptan is comparable to that of placebo and significantly lower than that with sumatriptan. Drug-drug interaction studies indicate that almotriptan may be coadministered with other commonly prescribed drugs without dose modification. Almotriptan can be recommended as first-line treatment for acute migraine.",
keywords = "Adverse events, Almotriptan, Efficacy, Migraine, Triptans",
author = "Dodick, {David William}",
year = "2003",
month = "7",
day = "1",
doi = "10.1517/eoph.4.7.1157.21072",
language = "English (US)",
volume = "4",
pages = "1157--1163",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - A review of the clinical efficacy and tolerability of almotriptan in acute migraine

AU - Dodick, David William

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Almotriptan is a serotonin (5-hydroxytryptamine, 5-HT)1B/1D-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consistency of response across three attacks and patients continue to respond to almotriptan for up to 1 year. Results from two comparative studies and a meta-analysis of 53 randomised, placebo-controlled studies of oral triptans in > 24,000 patients, confirm that almotriptan 12.5 mg demonstrates comparable efficacy with sumatriptan 50 and 100 mg. The incidence of treatment-related adverse events with almotriptan is comparable to that of placebo and significantly lower than that with sumatriptan. Drug-drug interaction studies indicate that almotriptan may be coadministered with other commonly prescribed drugs without dose modification. Almotriptan can be recommended as first-line treatment for acute migraine.

AB - Almotriptan is a serotonin (5-hydroxytryptamine, 5-HT)1B/1D-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consistency of response across three attacks and patients continue to respond to almotriptan for up to 1 year. Results from two comparative studies and a meta-analysis of 53 randomised, placebo-controlled studies of oral triptans in > 24,000 patients, confirm that almotriptan 12.5 mg demonstrates comparable efficacy with sumatriptan 50 and 100 mg. The incidence of treatment-related adverse events with almotriptan is comparable to that of placebo and significantly lower than that with sumatriptan. Drug-drug interaction studies indicate that almotriptan may be coadministered with other commonly prescribed drugs without dose modification. Almotriptan can be recommended as first-line treatment for acute migraine.

KW - Adverse events

KW - Almotriptan

KW - Efficacy

KW - Migraine

KW - Triptans

UR - http://www.scopus.com/inward/record.url?scp=0038783508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038783508&partnerID=8YFLogxK

U2 - 10.1517/eoph.4.7.1157.21072

DO - 10.1517/eoph.4.7.1157.21072

M3 - Article

C2 - 12831340

AN - SCOPUS:0038783508

VL - 4

SP - 1157

EP - 1163

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -